## **Supplementary information**

## Human NMD ensues independently of stable ribosome stalling

Evangelos D. Karousis, Lukas-Adrian Gurzeler, Giuditta Annibaldis, René Dreos and Oliver Mühlemann

### Supplementary Figure 1: Optimization of in vitro translation conditions



**a.** *In vitro* translation using different concentrations of 200+pA mRNA. Rluc activity measurements are depicted as arbitrary units (AU) of luminescence. The dots depict the values of two individual experiments. **b.** Time-course of 200+pA in vitro translation reaction using 40 fmol/µL. Rluc activity measurements are depicted as in (a), mean values and SD of three indepent experiments are shown. **c.** Mg<sup>2+</sup> titration for in vitro translation reactions using 40 fmol/µL 200+pA mRNA as substrate. Rluc activity measurements are depicted as in (a). **d.** Toeprint analysis with reporter mRNA containing a 200 nts long 3'UTR and an 80 nts long poly(A) tail (200+pA). *In vitro* translation was performed in large scale (from > 10<sup>8</sup> cells, yielding > 500 µl lysate) or small-scale lysates (from < 4x10<sup>7</sup> cells, yielding less than 200 µl lysate). Translation-competent HeLa lysates were incubated for 50 min in the presence or absence of puromycin and the toeprint reactions were performed under different MgCl<sub>2</sub> concentrations. Sanger sequencing reactions were run in parallel (G, T, C, A). The positions of termination codon (TC) and the toeprint band 18 nucleotides downstream of the first nucleotide of the TC (+18), corresponding to ribosomes located at the TC, are indicated. Source data are provided as a Source Data File.

Supplementary Figure 2: Assessment of degradation in the context of toeprint assays

а	RRL Reporter r	nRNA			200	+pA		
	Translatio	n		-	F			-
	Puromycii	n		-		+		-
	Additional	treatment	-	95°C	PC		-	PC
	out they are they				and the			
	and design of the second							
	all the second sec							
		100000		and the second			and the second	
		1000 1000 1000 1000 1000 1000 1000 100					-	1000
TC-			-	-		*		
			-		-	*		
		- 1000						
+18-			-	-		*		
		-						
_	GΤ	C A	1	2	3	4	5	6

b



#### **Supplementary Figure 2**

**a.** Toeprint analysis with the 200+pA reporter RNA translated in rabbit reticulocyte lysate (RRL) for 30 min in the presence or absence of puromycin. The toeprint reaction was performed after either incubation at 95°C to denature proteins and ribosomal complexes (95°C) or by phenol-chloroform extraction (PC). To visualize co-translational degradation products, untranslated RNA was extracted in parallel. Sanger sequencing reactions were run in parallel (G, T, C, A) to locate the positions of the signals. The position of the TC and the toeprint band corresponding to the ribosomes at the TC (+18) are indicated. Translation-dependent cleavage products are depicted by asterisks.

**b.** Toeprint analysis with the 200+pA reporter mRNA translated in translation-competent HeLa lysates for 50 min. Before the reverse transcription step, phenol-chloroform extraction (PC) was performed to identify potential co-translational RNA cleavage events. Sanger sequencing reactions were run in parallel (G, T, C, A) to locate the positions of the toeprints. The position of the TC and the toeprint band corresponding to the ribosomes at the TC (+18) are indicated. Source data are provided as a Source Data File.

### **Supplementary Figure 3**



Relative levels of a TCR- $\beta$  NMD reporter mRNA and the endogenous NMD-sensitive Retinitis Pigmentosa 9 Pseudogene (RP9P) mRNA measured by RT-qPCR from cells depleted for UPF1 (UPF1 KD) or with a control knockdown (CTRL KD) and expressing either of the Rluc reporter genes 200+pA or 1400+pA. Mean values ± standard deviations of 3 biological replicates are shown, values of the individual experiments are indicated by dots.

## List of primers and RNA oligonucleotides

Ampicillin resistance gene	5'-AAT TTC TAG AAT TGT TGC CGG GAA GCT AGA GTA AG-3'				
amplification	5'-AAT TTC TAG ATG AGT ATT CAA CAT TTC CGT GTC G-3'				
Site directed mutagenesis	5'-CAA ATG TGG TAT GGC TGA TTA GAT CCT CTA GAA TTC CTG				
Reporter A	CTC-3'				
Site directed mutagenesis	5'-CAA ATG TGG TAT GGC TGA TTA GAT CCT CAA GAA TTC CTG				
Reporter B	CTC-3′				
Site directed mutagenesis	5'-AAA TGT GGT ATG GCT GAT TGG ATC CTC AAG AAT TCC TGC-				
Reporter C	3′				
RLuc ORF amplification	5'-GGG CCC ATG GCT TCC AAG GTG TAC GA-3' and 5'-GGT ACC				
	AAC AAC AAT TGC ATT CA-3′				
	5'-GGT ACC AAC AAC AAC AAT TGC ATT CA-3'				
Site directed mutagenesis	5'-CTG GCT AGC GTT TAA ACG CCA CCA TGG CTT CCA AGG TGT-				
Reporter Kozak sequence	3′				
Fusion PCR for p1400	Fragment 1:				
	5'-GGG CCC ATG GCT TCC AAG GTG TAC GA-3' and 5'-TGG CGA				
	TGA GAA CAA CAA TTG CAT TCA-3′				
	Fragment 2:				
	Fragment 2: 5′-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3′ and 5′-GGT				
	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3'				
Toeprint primer	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3'				
Toeprint primer UPF1 siRNA	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay Mini-TCRβ reporter qPCR	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay Mini-TCRβ reporter qPCR assay	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3' 5'-CTT GGG TGG AGT CAC ATT TC-3'				
Toeprint primerUPF1 siRNAABCE1 siRNANegative CTR siRNAbeta-actin qPCR assayMini-TCRβ reporter qPCRassayRetinitis Pigmentosa 9	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3' 5'-CTT GGG TGG AGT CAC ATT TC-3' 5'-CAA GCG CCT GGA GTC CTT AA-3'				
Toeprint primerUPF1 siRNAABCE1 siRNANegative CTR siRNAbeta-actin qPCR assayMini-TCRβ reporter qPCR assayRetinitis Pigmentosa 9Pseudogene (RP9P) qPCR	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3' 5'-CTT GGG TGG AGT CAC ATT TC-3' 5'-CAA GCG CCT GGA GTC CTT AA-3' 5'-AGG AGG TTT TTC ATA ACT CGT GAT CT-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay Mini-TCRβ reporter qPCR assay Retinitis Pigmentosa 9 Pseudogene (RP9P) qPCR assay	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3' 5'-CAT GGG TGG AGT CAC ATT TC-3' 5'-CAA GCG CCT GGA GTC CTT AA-3' 5'-AGG AGG TTT TTC ATA ACT CGT GAT CT-3'				
Toeprint primer UPF1 siRNA ABCE1 siRNA Negative CTR siRNA beta-actin qPCR assay Mini-TCRβ reporter qPCR assay Retinitis Pigmentosa 9 Pseudogene (RP9P) qPCR assay humanized Renilla	Fragment 2: 5'-TGT TGT TGT TCT CAT CGC CAA TTG TTG CC-3' and 5'-GGT ACC CTA GAT GAG TAT TC-3' 5'-TCA GGT TCA GGG GGA GGT G-3' 5'-GAUGCAGUUCCGCUCCAUU-3' 5'-GAG GAG AGU UGC AGA GAU UU dTdT-3' 5'-AGG UAG UGU AAU CGC CUU G dTdT-3' 5'-TCC ATC ATG AAG TGT GAC GT-3' 5'-TAC TCC TGC TTG CTG ATC CAC-3' 5'-AGT TGG CTT CCC TTT CTC AG-3' 5'-CTT GGG TGG AGT CAC ATT TC-3' 5'-CAA GCG CCT GGA GTC CTT AA-3' 5'-AGG AGG TTT TTC ATA ACT CGT GAT CT-3' 5'-CCC CGA GCA ACG CAA AC-3'				

# **Supplementary Table 1**